Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...

Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere's Disease SAN DIEGO, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...

Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Second Label Expansion Indication SAN DIEGO, July 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...

Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067 Achieved statistical significance on...